{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:30:07Z","timestamp":1773797407699,"version":"3.50.1"},"reference-count":61,"publisher":"American Diabetes Association","issue":"Supplement_2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":200,"URL":"http:\/\/www.diabetesjournals.org\/site\/license"}],"funder":[{"name":"Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:p>Treatment with insulin, alone or with oral or injectable hypoglycemic agents, is becoming increasingly common in patients with type 2 diabetes. However, approximately 40% of patients fail to reach their glycemic targets with the initially prescribed regimen and require intensification of insulin therapy, which increases the risks of weight gain and hypoglycemia. Many of these patients eventually reach a state in which further increases in the insulin dosage fail to improve glycemic control while increasing the risks of weight gain and hypoglycemia. The recently completed OpT2mise clinical trial showed that continuous subcutaneous insulin infusion (CSII) is more effective in reducing glycated hemoglobin (HbA1c) than intensification of multiple daily injection (MDI) insulin therapy in patients with type 2 diabetes who do not respond to intensive insulin therapy. CSII therapy may also be useful in patients who do not reach glycemic targets despite multidrug therapy with basal-bolus insulin and other agents, including glucagon-like peptide (GLP)-1 receptor agonists; current guidelines offer no recommendations for the treatment of such patients. Importantly, insulin and GLP-1 receptor agonists have complementary effects on glycemia and, hence, can be used either sequentially or in combination in the initial management of diabetes. Patients who have not previously failed GLP-1 receptor agonist therapy may show reduction in weight and insulin dose, in addition to moderate improvement in HbA1c, when GLP-1 receptor agonist therapy is added to MDI regimens. In subjects with long-standing type 2 diabetes who do not respond to intensive insulin therapies, switching from MDI to CSII and\/or the addition of GLP-1 receptor agonists to MDI have the potential to improve glycemic control without increasing the risk of adverse events.<\/jats:p>","DOI":"10.2337\/dcs15-3029","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T09:52:32Z","timestamp":1469008352000},"page":"S180-S186","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":11,"title":["When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump"],"prefix":"10.2337","volume":"39","author":[{"given":"Ohad","family":"Cohen","sequence":"first","affiliation":[{"name":"Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Filetti","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Interna e Specialit\u00e0 Mediche, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Casta\u00f1eda","sequence":"additional","affiliation":[{"name":"Medtronic Bakken Research Center, Maastricht, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Maranghi","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Interna e Specialit\u00e0 Mediche, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariela","family":"Glandt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Bronx-Lebanon Hospital, Bronx, NY, and Center for Diabetes Care, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2016,7,16]]},"reference":[{"key":"2022031219431923700_B1","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"key":"2022031219431923700_B2","unstructured":"International Diabetes Federation. IDF Diabetes Atlas - 7th edition [Internet]. Available from http:\/\/www.diabetesatlas.org\/. Accessed 15 January 2016"},{"key":"2022031219431923700_B3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2337\/dc07-1572","article-title":"Is glycemic control improving in U.S. adults?","volume":"31","author":"Hoerger","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031219431923700_B4","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031219431923700_B5","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.2337\/dcS13-2027","article-title":"Insulin pump for type 2 diabetes: use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes","volume":"36","author":"Reznik","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031219431923700_B6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0140-6736(14)61037-0","article-title":"Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial","volume":"384","author":"Reznik","year":"2014","journal-title":"Lancet"},{"key":"2022031219431923700_B7","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.2337\/diacare.26.9.2598","article-title":"Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study","volume":"26","author":"Raskin","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031219431923700_B8","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.2337\/diacare.28.7.1568","article-title":"A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes","volume":"28","author":"Herman","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031219431923700_B9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-2007-970423","article-title":"Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure","volume":"39","author":"Berthe","year":"2007","journal-title":"Horm Metab Res"},{"key":"2022031219431923700_B10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1464-5491.2005.01597.x","article-title":"Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients","volume":"22","author":"Wainstein","year":"2005","journal-title":"Diabet Med"},{"key":"2022031219431923700_B11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cell.2014.09.048","article-title":"Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis","volume":"159","author":"Thaiss","year":"2014","journal-title":"Cell"},{"key":"2022031219431923700_B12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1089\/dia.2013.0363","article-title":"OpT2mise: a randomized controlled trial to compare insulin pump therapy with multiple daily injections in the treatment of type 2 diabetes-research design and methods","volume":"16","author":"Aronson","year":"2014","journal-title":"Diabetes Technol Ther"},{"key":"2022031219431923700_B13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.diabet.2007.01.007","article-title":"Long-term treatment combining continuous subcutaneous insulin infusion with oral hypoglycaemic agents is effective in type 2 diabetes","volume":"33","author":"Labrousse-Lhermine","year":"2007","journal-title":"Diabetes Metab"},{"key":"2022031219431923700_B14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1089\/dia.2010.0110","article-title":"Efficacy of continuous subcutaneous insulin infusion in type 2 diabetes mellitus: a survey on a cohort of 102 patients with prolonged follow-up","volume":"12","author":"Reznik","year":"2010","journal-title":"Diabetes Technol Ther"},{"key":"2022031219431923700_B15","unstructured":"Swedish National Diabetes Register. Annual report 2013 [Internet]. Available from https:\/\/www.ndr.nu\/pdfs\/Annual_Report_NDR_2013.pdf. Accessed 15 July 2015"},{"key":"2022031219431923700_B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1463-1326.2011.01469.x","article-title":"The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern","volume":"14","author":"Currie","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031219431923700_B17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/dom.12412","article-title":"Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer","volume":"17","author":"Holden","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031219431923700_B18","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1177\/1932296814533171","article-title":"Autonomy of patients with type 2 diabetes with an insulin pump device: is it predictable","volume":"8","author":"Reznik","year":"2014","journal-title":"J Diabetes Sci Technol"},{"key":"2022031219431923700_B19"},{"key":"2022031219431923700_B20","first-page":"500","year":"2016"},{"key":"2022031219431923700_B21","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","article-title":"Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial","volume":"371","author":"Weng","year":"2008","journal-title":"Lancet"},{"key":"2022031219431923700_B22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1530\/acta.0.1180365","article-title":"Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes","volume":"118","author":"Glaser","year":"1988","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2022031219431923700_B23","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2337\/diacare.20.9.1353","article-title":"Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment","volume":"20","author":"Ilkova","year":"1997","journal-title":"Diabetes Care"},{"key":"2022031219431923700_B24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"Inzucchi","year":"2015","journal-title":"Diabetologia"},{"key":"2022031219431923700_B25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4158\/EP15693.CS","article-title":"AACE\/ACE comprehensive diabetes management algorithm 2015","volume":"21","author":"Garber","year":"2015","journal-title":"Endocr Pract"},{"key":"2022031219431923700_B26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/dc07-1122","article-title":"Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension\/lispro) versus basal\/bolus (glargine\/lispro) therapy","volume":"31","author":"Rosenstock","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031219431923700_B27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/dom.12225","article-title":"Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections","volume":"16","author":"Riddle","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031219431923700_B28","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/jama.2013.276131","article-title":"Cost-effectiveness of bariatric surgery","volume":"310","author":"Maciejewski","year":"2013","journal-title":"JAMA"},{"key":"2022031219431923700_B29","unstructured":"National Institute for Health and Care Excellence. Type 2 diabetes in adults: management: NICE guidelines [NG28] [Internet], 2015. Available from http:\/\/www.nice.org.uk\/guidance\/ng28. Accessed 15 January 2016"},{"key":"2022031219431923700_B30","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.2337\/diacare.24.12.2078","article-title":"Use of insulin pumps in pregnancies complicated by type 2 diabetes and gestational diabetes in a multiethnic community","volume":"24","author":"Simmons","year":"2001","journal-title":"Diabetes Care"},{"key":"2022031219431923700_B31","first-page":"A360","article-title":"Reduction of complications and associated costs for type 2 diabetic patients using continuous subcutaneous insulin infusion in the Uk","volume":"18","author":"Roze","year":"2015","journal-title":"Value Health"},{"key":"2022031219431923700_B32","first-page":"e418","article-title":"Clinical inertia in patients with T2DM requiring insulin in family practice","volume":"56","author":"Harris","year":"2010","journal-title":"Can Fam Physician"},{"key":"2022031219431923700_B33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031219431923700_B34","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2022031219431923700_B35","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/dme.13021","article-title":"Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira","volume":"33","author":"Wilding","year":"2016","journal-title":"Diabet Med"},{"key":"2022031219431923700_B36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4239\/wjd.v5.i1.40","article-title":"Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes","volume":"5","author":"Ahr\u00e9n","year":"2014","journal-title":"World J Diabetes"},{"key":"2022031219431923700_B37","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1089\/dia.2010.0221","article-title":"The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements","volume":"13","author":"Lane","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"2022031219431923700_B38","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1463-1326.2010.01356.x","article-title":"Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes","volume":"13","author":"Garber","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031219431923700_B39","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","article-title":"A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"51","author":"Rosenstock","year":"2008","journal-title":"Diabetologia"},{"key":"2022031219431923700_B40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"2022031219431923700_B41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"2022031219431923700_B42","author":"Riddle"},{"key":"2022031219431923700_B43","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031219431923700_B44","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/dom.12539","article-title":"Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"17","author":"Ahmann","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031219431923700_B45","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jdiacomp.2014.07.007","article-title":"Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis","volume":"28","author":"Charbonnel","year":"2014","journal-title":"J Diabetes Complications"},{"key":"2022031219431923700_B46","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13300-015-0142-y","article-title":"IDegLira versus alternative intensification strategies in patients with type 2 diabetes inadequately controlled on basal insulin therapy","volume":"6","author":"Freemantle","year":"2015","journal-title":"Diabetes Ther"},{"key":"2022031219431923700_B47","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","article-title":"Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study","volume":"385","author":"Blonde","year":"2015","journal-title":"Lancet"},{"key":"2022031219431923700_B48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/dom.12624","article-title":"Patient-reported outcome results in patients with type 2 diabetes treated with once weekly dulaglutide: data from the AWARD Phase 3 clinical trial programme","volume":"18","author":"Yu","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2022031219431923700_B49","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc14-0876","article-title":"Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes","volume":"37","author":"Diamant","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031219431923700_B50","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/dc14-0001","article-title":"Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031219431923700_B51","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/dom.12286","article-title":"The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial","volume":"16","author":"Lane","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031219431923700_B52","doi-asserted-by":"crossref","first-page":"h5364","DOI":"10.1136\/bmj.h5364","article-title":"Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)","volume":"351","author":"Lind","year":"2015","journal-title":"BMJ"},{"key":"2022031219431923700_B53","article-title":"Design of FLAT-SUGAR: randomized trial of prandial insulin versus prandial GLP-1 receptor agonist together with basal insulin and metformin for high-risk type 2 diabetes","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031219431923700_B54","first-page":"523","article-title":"A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice","volume":"72","author":"van Velsen","year":"2014","journal-title":"Neth J Med"},{"key":"2022031219431923700_B55","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4158\/EP.13.5.444","article-title":"Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin","volume":"13","author":"Viswanathan","year":"2007","journal-title":"Endocr Pract"},{"key":"2022031219431923700_B56","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.clinthera.2009.07.021","article-title":"Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting","volume":"31","author":"Yoon","year":"2009","journal-title":"Clin Ther"},{"key":"2022031219431923700_B57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s13300-014-0093-8","article-title":"Liraglutide as add-on therapy to insulin in type 2 diabetes mellitus: a retrospective, observational study from a daily clinical practice setting in Switzerland","volume":"6","author":"Lipowsky","year":"2015","journal-title":"Diabetes Ther"},{"key":"2022031219431923700_B58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pcd.2011.09.002","article-title":"Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction","volume":"6","author":"Lind","year":"2012","journal-title":"Prim Care Diabetes"},{"key":"2022031219431923700_B59","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The scale diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"2022031219431923700_B60"},{"key":"2022031219431923700_B61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diabet.2015.03.004","article-title":"Using the respective contributions of postprandial and basal glucose for tailoring treatments in type 2 diabetes","volume":"41","author":"Monnier","year":"2015","journal-title":"Diabetes Metab"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dcS15-3029","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/Supplement_2\/S180\/547836\/dcs153029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/Supplement_2\/S180\/547836\/dcs153029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T21:25:41Z","timestamp":1647120341000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/39\/Supplement_2\/S180\/30012\/When-Intensive-Insulin-Therapy-MDI-Fails-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,16]]},"references-count":61,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2016,7,16]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dcs15-3029","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,16]]}}}